Angion Provides Corporate Update and Reports Full Year 2021 Financial Results
March 30, 2022 16:05 ET
|
Angion Biomedica Corp.
-- Enrollment continues in Phase 2 JUNIPER trial of ANG-3070 for the treatment of patients with primary proteinuric kidney diseases -- Ended the year with nearly $89M in cash and cash equivalents ...
Angion Announces Participation in Upcoming Investment Conferences
February 28, 2022 16:05 ET
|
Angion Biomedica Corp.
UNIONDALE, N.Y., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small...
Angion Provides Corporate Update and Announces Participation in Upcoming Investor Conference
January 04, 2022 16:05 ET
|
Angion Biomedica Corp.
-- First patient enrolled in the Phase 2 trial of ANG-3070 in primary proteinuric kidney diseases -- Angion will end 2021 with approximately $88.8 million in cash and cash equivalents UNIONDALE,...
Angion Provides Corporate Update and Reports Third Quarter 2021 Financial Results
November 12, 2021 07:00 ET
|
Angion Biomedica Corp.
UNIONDALE, N.Y., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Angion Presents Multiple Posters on ANG-3070 at Kidney Week 2021, Including Preclinical Data and Design of Upcoming Phase 2 Study
November 05, 2021 00:05 ET
|
Angion Biomedica Corp.
UNIONDALE, N.Y., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Angion to Present Multiple Posters at Kidney Week 2021
October 18, 2021 16:05 ET
|
Angion Biomedica Corp.
UNIONDALE, N.Y., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Angion Hosting Research & Development Day on ANG-3070 for the Treatment of Lung and Kidney Fibrosis
September 08, 2021 00:05 ET
|
Angion Biomedica Corp.
UNIONDALE, N.Y., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Nash Pharmaceuticals Announces Positive Pre-Clinical Results For Its Lead Compound NP-135 in Chronic Kidney Disease
November 19, 2018 07:00 ET
|
Breathtec Biomedical Inc.
Planning Phase II Trial VANCOUVER, B.C., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI)...